Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to -$0.25.

  • Iovance Biotherapeutics' EPS (Basic) rose 1071.43% to -$0.25 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.19, marking a year-over-year increase of 2013.42%. This contributed to the annual value of -$1283.9 for FY2024, which is 6783193.24% down from last year.
  • Iovance Biotherapeutics' EPS (Basic) amounted to -$0.25 in Q3 2025, which was up 1071.43% from -$0.33 recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' EPS (Basic) ranged from a high of -$0.25 in Q3 2025 and a low of -$271.06 during Q4 2024
  • For the 3-year period, Iovance Biotherapeutics' EPS (Basic) averaged around -$24.99, with its median value being -$0.42 (2024).
  • Examining YoY changes over the last 5 years, Iovance Biotherapeutics' EPS (Basic) showed a top increase of 3913.04% in 2024 and a maximum decrease of 6013474.32% in 2024.
  • Over the past 3 years, Iovance Biotherapeutics' EPS (Basic) (Quarter) stood at -$0.45 in 2023, then plummeted by 60134.74% to -$271.06 in 2024, then surged by 99.91% to -$0.25 in 2025.
  • Its last three reported values are -$0.25 in Q3 2025, -$0.33 for Q2 2025, and -$0.36 during Q1 2025.